BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
Rhea-AI Summary
BrainsWay (NASDAQ: BWAY) will report first-quarter 2026 financial results and operational highlights before U.S. markets open on Wednesday, May 13, 2026. A live conference call and webcast are scheduled for 8:30 AM ET, with replay available for 30 days on the company investor website.
Dial-in, conference ID and webcast registration details are provided; attendees are asked to join at least 10 minutes early to register.
Positive
- None.
Negative
- None.
News Market Reaction – BWAY
In the Apr 29 session, BWAY declined 1.37%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings date notice | Neutral | +0.2% | Announced date and call details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news led to minimal share price movement.
Recent news for BrainsWay has included operational and strategic updates, with this release setting the date and time for Q1 2026 results on May 13, 2026. A prior earnings-date announcement on Feb 25, 2026 produced a modest 0.16% move, indicating that simple scheduling notices have historically not been major trading catalysts compared to full earnings releases or strategic transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its first quarter 2026 financial results and recent operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Wednesday, May 13, 2026 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Conference ID: | 10208547 |
| Webcast: | Link |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
